SS-31 research record explained: Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy:

Quick answer

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” a phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹

This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.¹ For Filipino readers, “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment” is best read by matching every conclusion to the exact study, population, outcome, and product identity.

What did this SS-31 record actually examine?

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” start with the recorded result, not the marketing version. A phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.¹ This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.¹

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” the clearest route is to separate the result from its interpretation. WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.²

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” WHO guidance on suspected falsified medical products and regulatory laboratory testing.² Appearance alone cannot authenticate a product or establish a research outcome.²

In “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” the careful reading is narrower than a social-media headline. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

The plain-language rule for “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment” is simple: identify what was measured before asking what it might mean elsewhere. A precise answer can still be interesting; it simply keeps the reader oriented.

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What was the main finding?

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” one precise finding is more useful than a broad slogan. In a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.³

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.³ This was an open-label study with a small number of participants, and all knew they were receiving the active drug.³

That distinction gives “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment” a useful answer without making it sound larger than the evidence. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” the study becomes easier to read when its boundaries remain visible. A study record is most useful when its reported result remains attached to the population, design, source identifier, and exact product identity.⁴

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” Editorial synthesis of the canonical research records and Philippine verification sources.⁴ This synthesis is educational and is not personal medical advice or a product recommendation.⁴

Keeping that boundary visible makes “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment” clearer for a general reader. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

A useful magazine explanation of “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment” should make the main point easy to find. It should also keep the study boundary close enough that readers do not need to hunt for it.

Which study details change the interpretation?

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” a useful summary begins with the outcome the researchers actually recorded. In a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.⁵

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.⁵ This is an animal study, and the result is for the combination, not elamipretide alone.⁵

What should not be borrowed from the result?

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” start with the recorded result, not the marketing version. SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.⁶

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.⁶ This is a description of its mechanism of action from regulatory and laboratory sources.⁶

How does the wider evidence sharpen the picture?

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” one precise finding is more useful than a broad slogan. In a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁷

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁷ The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁷

A catalog card does not change the evidence boundary in “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment”.⁴ It helps readers locate a live item while the article keeps scientific and product questions separate.⁴

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers verify next?

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” a useful summary begins with the outcome the researchers actually recorded. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸

Within “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” Official Philippine regulatory verification service.⁸ A portal record applies to the exact product or establishment named in that record.⁸

Bottom line

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” the randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.¹ This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.¹

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸ For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” this check belongs beside the science rather than underneath it.

For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” the sound conclusion keeps the source, study context, and product identity separate.

Frequently asked questions

What is the fastest way to understand SS-31?

A phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.¹ For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” begin there, then keep the study setting and stated limit beside the result instead of jumping to a broader conclusion.

Does one positive finding settle the whole topic?

No. This was an open-label study with a small number of participants, and all knew they were receiving the active drug.³ In “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” a finding can be useful while remaining narrow, early, or tied to one measured outcome.

Why does the study context matter?

The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.⁵ For “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” changing the population, design, formulation, or outcome changes the question being answered.

What should Filipino readers verify?

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸ While reading “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” check the exact product and establishment details rather than relying on a familiar molecule name.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In “SS-31: Elamipretide Topical Ophthalmic Solution for the Treatment,” they are live catalog references for navigation. They do not turn a study result into a product claim, prove equivalence, or suggest using the items together.⁴

Sources

Footnotes

1. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.. The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point. This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩² ↩³

3. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³ ↩⁴

4. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy. This is an animal study, and the result is for the combination, not elamipretide alone. ↩ ↩² ↩³ ↩⁴

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³

7. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³

8. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵